Under the terms of the contract, Kromek will supply its cadmium zinc telluride-based (CZT) detector modules for incorporation in the customer’s products. The density of CZT means that its incorporation significantly improves the sensitivity of positive detection of cancerous tumours.
Dr Arnab Basu, CEO of Kromek, said: “I am pleased to receive this long-term contract from our existing customer reaffirming their commitment for the next five years. This is a result of the high-quality products and services we have provided them throughout the last few years. We are continuing to develop new business opportunities in our core markets while serving our existing customers, which are important for the continuing growth of the business.”